Fractyl Health (NASDAQ:GUTS) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Fractyl Health (NASDAQ:GUTS) posted its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports.

Here are the key takeaways from Fractyl Health’s conference call:

• Revita’s one-year randomized data showed durable weight maintenance: patients retained more than 80% of prior GLP-1-induced weight loss versus 46% for sham, with no device- or procedure-related serious adverse events reported.
• The company said the REMAIN-1 pivotal trial is fully randomized with more than 300 participants across 30-plus sites, and remains on track to report six-month top-line data in early Q4 2026 and potentially submit for FDA De Novo authorization in late Q4.
• Management sees a sizable commercial opportunity driven by continued GLP-1 use and discontinuation, payer concerns over indefinite treatment costs and frailty, and a targeted center-of-excellence launch model with potential CMS transitional pass-through reimbursement.
• Fractyl ended Q2 with $47.1 million in cash and said its runway extends into early 2027, beyond pivotal data and a potential De Novo submission; however, the regulatory pathway remains contingent on FDA review of the complete safety dataset, and no capital raise is planned before pivotal data.
• The company received authorization in the Netherlands and ethics approval in Australia to begin the first-in-human Phase I/II study of its Rejuva gene-therapy candidate, with initial safety and delivery-feasibility data expected in the second half of 2026.

Fractyl Health Stock Performance

Fractyl Health stock opened at $0.68 on Tuesday. The firm has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $0.70. The stock has a market cap of $107.09 million, a price-to-earnings ratio of -0.52 and a beta of 2.32. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $2.44.

Insider Buying and Selling

In other Fractyl Health news, Director William Bradley acquired 68,493 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the transaction, the director owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. The trade was a 424.66% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ian Sheffield purchased 35,000 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the purchase, the director owned 35,000 shares in the company, valued at approximately $25,550. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 171,493 shares of company stock worth $127,150 over the last quarter. 8.52% of the stock is currently owned by insiders.

Institutional Trading of Fractyl Health

Several institutional investors and hedge funds have recently made changes to their positions in GUTS. Nantahala Capital Management LLC purchased a new stake in shares of Fractyl Health in the third quarter valued at about $19,298,000. Marshall Wace LLP lifted its stake in shares of Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after acquiring an additional 4,156,969 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of Fractyl Health in the third quarter valued at about $8,981,000. Woodline Partners LP raised its holdings in Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after purchasing an additional 4,908,693 shares in the last quarter. Finally, General Catalyst Group Management LLC purchased a new stake in Fractyl Health in the 2nd quarter valued at approximately $7,912,000.

Wall Street Analysts Forecast Growth

GUTS has been the subject of several recent analyst reports. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Craig Hallum assumed coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They set a “buy” rating and a $4.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, June 4th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Fractyl Health currently has a consensus rating of “Moderate Buy” and an average price target of $5.12.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.